Treatment of idiopathic inflammatory myopathies using a population of CD19 car-expressing cells
Engineering CD19 CAR-expressing cell populations to treat IIM addresses the lack of effective therapies by modulating the immune response, offering substantial clinical benefits for refractory cases.
TW202629785APending Publication Date: 2026-07-16NOVARTIS AG
0 Cites 0 Cited by
Patent Information
- Application Number
- TW114141419
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-10-28
- Filing Date
- 2025-10-27
- Publication Date
- 2026-07-16
AI Technical Summary
Technical Problem
Current treatments for idiopathic inflammatory myopathies (IIM) are inadequate, particularly for refractory cases, lacking effective therapies that can manage muscle weakness and systemic involvement, and there are no standardized treatment guidelines.
Method used
Administration of a cell population engineered to express CD19 chimeric antigen receptors (CAR), specifically tailored to maintain or modify certain T cell subsets and gene set scores, along with potential adjunct therapies like rapcabtagene autoleucel or retalicylate, to modulate the immune response.
Benefits of technology
The approach provides significant improvement in refractory IIM patients, reducing disease activity and improving muscle function, with potential for sustained remission and reduced relapse.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention provides methods of using a population of CD19 CAR-expressing cells (for example, rapcabtagene autoleucel) for treating idiopathic inflammatory myopathies. Also disclosed are methods of making a population of CD19 CAR-expressing cells.
Need to check novelty before this filing date? Find Prior Art